News for 'ajanta-pharma'

Abbott Bets On Semaglutide Boom

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.

Ajanta Pharma reissues shares

Ajanta Pharma Ltd reissued 250 equity shares, earlier forfeited by the company.

Ajanta Pharma, Medicago join hands for flu vaccine

Mumbai-based Ajanta Pharma has tied up with the Canadian vaccine maker, Medicago Inc, to commercialise Medicago's pandemic and seasonal influenza vaccines in India and other territories.

Lower input costs may aid pharma firms' Q2 margins

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.

Largecap, midcap cutoff surges over 26% in latest Amfi classification

The rally in the equity markets in the second half of 2023 has led to a sharp surge in the cutoff for stocks to qualify as largecaps and midcaps. On the latest list put out by the Association of Mutual Funds in India (Amfi), the smallest largecap stock now has a market capitalisation (m-cap) of Rs 67,000 crore, 35 per cent higher than in July 2023. In the case of midcaps, the cutoff has surged 26 per cent to Rs 22,000 crore.

Check The Management Before Investing

A lot depends upon the crucial decision-making skills of the management. If you have any doubts about the management then you always have the choice of selling your shares or not buying stocks of those companies at all.

India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.

BSE drops Tata Power from Sensex; Lupin to come in

Adani Power will also be dropped from the S&P BSE 100 index

Volcker's findings: focus now on evidence

Corporates refute Volcker charge

Viagra? Drug firms rise to the occasion

How investors can fetch exceptional returns

TCS tops the list of 100 wealth creators for the fourth time in a row

Is my portfolio good?'

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

TCS, ITC biggest wealth creators during 2010-15

TCS created wealth worth Rs 3,458 billion for the period 2010-15.

BSE Midcap index set for worst monthly fall in 18 months

The BSE Midcap index has declined 5.7% thus far in May 2018. In comparison, the S&P BSE Small-cap index has lost 5.6%

Ask Ajit: Stocks to BUY, HOLD or SELL

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Mid-cap selloff: Don't press the panic button, say experts

Despite the recent fall, the Nifty Midcap 100 index has outperformed by gaining 20 per cent till date in this year calendar year.

Mid-cap selloff: Don't press the panic button, say experts

Despite the recent fall, the Nifty Midcap 100 index has outperformed by gaining 20 per cent till date in this year calendar year.

Note ban shadow lingers over one in four BSE 200 stocks

Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.

ASK AJIT: Stocks to hold or exit

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Tips to pick the right stocks and make big gains

Raamdeo's base argument is that India's stock market merely mirrors the national economy, which is poised for big things.

Sensex, Nifty jump over 1%; post third weekly gain

Rise in crude oil price and rally in global equities aided the sentiment

Drugs ban: Partial relief for Wockhardt, Glaxo & Griffon

The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.

'Hold or exit from these stocks?'

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Stocks that offered highest returns in Samvat 2071

The rally in most of these stocks is partly attributed to impressive financial performance.

Markets end flat; Commodity stocks rally

Bank shares were the top losers after sharp gains last week.

Stocks that shine year after year

The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.

Best and worst performing stocks in 2015

Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.

'Can't book profits in stock markets. Need help'

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Sensex snaps 4-day winning run as RBI holds rates

Financials ended mixed despite the status-quo on key rates by the RBI. SBI, ICICI Bank and Axis Bank ended up 0.4-2.5% each.

Do you own these stocks? EXIT them NOW

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

What shares should you invest in if you had Rs 5 lakh?

Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.

Markets sinking: Which stocks to buy, sell, hold

In an hour-long chat on rediff.com on Thursday, A K Prabhakar, senior VP and Head - Equity Research (Retail), Anand Rathi Financial Services Ltd, answered some important questions on the market.